- Question from Susan V: What about raloxifene use for postmenopausal women? Is it as good as or perhaps better for them?
- Answers - Charles Loprinzi Raloxifene (brand name: Evista) is a medication that is similar to tamoxifen. They are both termed as SERMS (selective estrogen receptor modifiers). With regard to treatment of recurrent breast cancer or treatment to try to prevent breast cancer, the vast majority of available evidence suggests that tamoxifen is superior to raloxifene. There is an ongoing study addressing the question of which of these two medications is better for preventing breast cancer in women who have never had breast cancer but are at risk for such. The acronym for this study is STAR (Study of Tamoxifen & Raloxifene). The one indication there is for raloxifene is for treatment of osteoporosis. Many oncologists, however, are not inclined to utilize raloxifene in women who have already had five years of tamoxifen.
On Wednesday, March 20, 2002, our Ask-the-Expert Online Conference was called Managing Menopausal Symptoms. Charles Loprinzi, M.D., Debra Barton, Ph.D., and Jennifer Griggs, M.D., M.P.H. answered your questions about hot flashes, vaginal dryness, loss of libido, and other symptoms associated with menopause.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.